Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ABP vs RADX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABP Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 3–2 Matrix Metrics)

ABP Overall Winner 6-Pillar Tally: ABP 2 – 2 RADX (2 Tie) Matrix Metrics: ABP 3 – 2 RADX

As of Nov 20, 2026, Abpro Holdings, Inc (ABP) is the stronger overall head-to-head candidate over Radiopharm Theranostics Limited (RADX) in the Tradestie Institutional Equity Comparison Engine, winning 3–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). ABP carries a Unified Composite Score of 44.4/100 (HOLD) at $0.52 (N/M Forward P/E, 0.0% operating margin), whereas RADX carries 41.1/100 (SELL) at $0.63 (N/M Forward P/E, -411.6% operating margin).

  • Growth vs. Quality Trade-Off: ABP earns the overall head-to-head edge with a stronger Unified Composite Score (44.4/100 HOLD vs. RADX 41.1/100 SELL) and 2.33β · 258% Vol risk profile, whereas RADX leads top-line expansion (-36.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ABP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.2); meanwhile RADX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ABP vs RADX
ABP NASDAQ Head-to-Head Winner
Abpro Holdings, Inc Common Stock
Biological Products, (No Disgnostic Substances)
$0.52
-34.76% 1D
Market Cap $2.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.33β · 258% Vol
Unified Composite Score
44.4 / 100 HOLD
Tech 40.0 Fund 49.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -36.3%), weak momentum, RSI 22
RSI-14: 22.2 · SMA20: $1.51 · SMA50: $3.29
RADX NASDAQ
Radiopharm Theranostics Limited American Depositary Shares
Pharmaceutical Preparations
$0.63
-6.33% 1D
Market Cap $10.6M
TTM Revenue $13M
Forward P/E N/M
Beta / 30D Vol 0.52β · 109% Vol
Unified Composite Score
41.1 / 100 SELL
Tech 25.0 Fund 45.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -33.5%), weak momentum, RSI 27
RSI-14: 26.9 · SMA20: $0.86 · SMA50: $1.15

6-Pillar Scorecard Institutional Category Breakdown (ABP 2 – 2 RADX)

Columns: Metric · ABP · RADX
1. Valuation Multiples RADX
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 0.8x
2. Growth & Scale RADX
Revenue Growth (YoY) -100.0% -36.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $13M
Market Cap $2.2M $10.6M
3. Profitability & Quality ABP
Gross Margin N/A N/A
Operating Margin 0.0% -411.6%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) 0.0% -174.7%
4. Balance Sheet & Cash Flow ABP
Cash Generation (TTM) N/A -$50M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage 0.0% ROE $1.48 Book/Sh · -174.7% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ABP (3) vs RADX (2)
Institutional Metric ABP RADX Criterion Row Edge
Market Capitalization
Scale
$2.2M $10.6M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-100.0% -36.9% Higher Growth RADX
Operating Margin (TTM)
Profitability
0.0% -411.6% Higher Margin ABP
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
0.0% -174.7% Higher ROE ABP
52-Week Range Position
Momentum
0% ($1–$32) 0% ($1–$16) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
2.33β · 258% Vol 0.52β · 109% Vol Lower Realized Risk RADX
Unified Institutional Score
Composite Signal
44.4 / 100 (HOLD) 41.1 / 100 (SELL) Higher Composite ABP
Trailing 12M Revenue (USD)
Operating Scale
N/A $13M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 0.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (0.0% ROE) -$50M EBITDA ($1.48 Book/Sh · -174.7% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RADX +86.09 pp
ABP: -84.04% · RADX: +2.05%
3M Horizon RADX +107.31 pp
ABP: -91.5% · RADX: +15.81%
6M Horizon RADX +101.36 pp
ABP: -91.06% · RADX: +10.3%
1Y Horizon RADX +101.36 pp
ABP: -91.06% · RADX: +10.3%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABP vs RADX. Trailing 12-month operating profitability (ABP 0.0% vs RADX -411.6%) and valuation multiples (ABP N/M vs RADX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ABP ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E0.0% · N/M
RADX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$13M
Gross MarginN/A
Op. Margin-411.6%
ROE / Fwd P/E-174.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ABP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ABP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RADX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RADX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ABP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
RADX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $10.6M market capitalization and -411.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ABP vs RADX Key Questions & Quantitative Answers

As of Nov 20, 2026, Abpro Holdings, Inc (ABP) is the stronger overall head-to-head candidate over Radiopharm Theranostics Limited (RADX) in the Tradestie Institutional Equity Comparison Engine, winning 3–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). ABP carries a Unified Composite Score of 44.4/100 (HOLD) at $0.52 (N/M Forward P/E, 0.0% operating margin), whereas RADX carries 41.1/100 (SELL) at $0.63 (N/M Forward P/E, -411.6% operating margin). Growth vs. Quality Trade-Off: ABP earns the overall head-to-head edge with a stronger Unified Composite Score (44.4/100 HOLD vs. RADX 41.1/100 SELL) and 2.33β · 258% Vol risk profile, whereas RADX leads top-line expansion (-36.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ABP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.2); meanwhile RADX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RADX leads the Growth & Scale pillar: ABP posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with RADX at -36.9% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (N/A gross margin, -411.6% operating margin). On trailing 12-month operating scale, ABP generates N/A in USD-normalized revenue versus $13M for RADX. In operating R&D and SG&A reinvestment, ABP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RADX.

RADX screens cheaper on headline valuation multiples. ABP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas RADX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.8x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABP (0.0% ROE) versus RADX (-174.7% ROE) capital efficiency.

In options market volatility and institutional positioning, ABP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.33β · 258% Vol realized risk). By comparison, RADX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.52β · 109% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.